Genomic prognostic indices in MF
| Prognostic Index/ Reference . | Prognostic factors . | Outcomes . | Notes . |
|---|---|---|---|
| MIPSS7015 | Hgb <10 g/dL WBC >25 × 103/µL Platelets <100 × 103/µL Circulating blasts ≥2% Constitutional symptoms Bone marrow fibrosis grade ≥2 No. of HMR mutations* Absence of type 1/like CALR mutation | Median OS, y Low risk: 27.7 Int risk: 7.1 High risk: 2.3 | Designed for PMF patients ≤70 y old |
| MIPSS70+15 | Hgb <10 g/dL WBC >25 × 103/µL Platelets <100 × 103/µL Circulating blasts ≥2% Constitutional symptoms No. of HMR mutations* Absence of type 1/like CALR mutation Unfavorable karyotype† | Median OS, y Low risk: 20 Int risk: 6.3 High risk: 3.9 Very high risk: 1.7 | Designed for PMF patients ≤70 y old |
| MIPSS70+ v2.016 | Severe or moderate anemia‡ Circulating blasts ≥2% Constitutional symptoms No. of HMR mutations§ Absence of type 1/like CALR mutation VHR or unfavorable karyotype|| | Median OS, y Very low risk: not reached Low risk: 16.4 Int risk: 7.7 High risk: 4.1 Very high risk: 1.8 | Designed for PMF patients ≤70 y old Assigns more points for severe anemia compared with moderate anemia Assigns more points for VHR karyotype compared with unfavorable karyotype |
| GIPSS17 | VHR or unfavorable karyotype|| Absence of type 1/like CALR mutation ASXL1 mutation SRSF2 mutation U2AF1 Q157 mutation | Median OS, y Low risk: 26.4 Int-1 risk: 8 Int-2 risk: 4.2 High risk: 2 | Designed for PMF Assigned greater points for unfavorable karyotype compared with very high-risk karyotype |
| MYSEC-PM18 | Age at diagnosis of SMF Hgb <11 g/dL Platelet <150 × 103/µL Circulating blasts ≥3% CALR unmutated Constitutional symptoms | Median OS, y Low risk: not reached Int-1 risk: 9.3 Int-2 risk: 4.4 High risk: 2 | Designed for SMF |
| Prognostic Index/ Reference . | Prognostic factors . | Outcomes . | Notes . |
|---|---|---|---|
| MIPSS7015 | Hgb <10 g/dL WBC >25 × 103/µL Platelets <100 × 103/µL Circulating blasts ≥2% Constitutional symptoms Bone marrow fibrosis grade ≥2 No. of HMR mutations* Absence of type 1/like CALR mutation | Median OS, y Low risk: 27.7 Int risk: 7.1 High risk: 2.3 | Designed for PMF patients ≤70 y old |
| MIPSS70+15 | Hgb <10 g/dL WBC >25 × 103/µL Platelets <100 × 103/µL Circulating blasts ≥2% Constitutional symptoms No. of HMR mutations* Absence of type 1/like CALR mutation Unfavorable karyotype† | Median OS, y Low risk: 20 Int risk: 6.3 High risk: 3.9 Very high risk: 1.7 | Designed for PMF patients ≤70 y old |
| MIPSS70+ v2.016 | Severe or moderate anemia‡ Circulating blasts ≥2% Constitutional symptoms No. of HMR mutations§ Absence of type 1/like CALR mutation VHR or unfavorable karyotype|| | Median OS, y Very low risk: not reached Low risk: 16.4 Int risk: 7.7 High risk: 4.1 Very high risk: 1.8 | Designed for PMF patients ≤70 y old Assigns more points for severe anemia compared with moderate anemia Assigns more points for VHR karyotype compared with unfavorable karyotype |
| GIPSS17 | VHR or unfavorable karyotype|| Absence of type 1/like CALR mutation ASXL1 mutation SRSF2 mutation U2AF1 Q157 mutation | Median OS, y Low risk: 26.4 Int-1 risk: 8 Int-2 risk: 4.2 High risk: 2 | Designed for PMF Assigned greater points for unfavorable karyotype compared with very high-risk karyotype |
| MYSEC-PM18 | Age at diagnosis of SMF Hgb <11 g/dL Platelet <150 × 103/µL Circulating blasts ≥3% CALR unmutated Constitutional symptoms | Median OS, y Low risk: not reached Int-1 risk: 9.3 Int-2 risk: 4.4 High risk: 2 | Designed for SMF |
GIPSS, Genetically Inspired Prognostic Scoring System; HMR, high molecular risk; MIPSS, Mutation-Enhanced International Prognostic Score System; MYSEC-PM, Myelofibrosis Secondary to PV and ET-Prognostic Model; SMF, secondary myelofibrosis; VHR, very high risk. See Table 1 for expansion of other abbreviations.
HMR mutations include ASXL1, SRSF2, EZH2, IDH1, and IDH2.
Unfavorable karyotype defined as any abnormal karyotype other than normal karyotype or sole abnormalities of 20q2, 13q2, +9, chromosome 1 translocation/duplication, 2Y, or sex chromosome abnormality other than 2Y.
Moderate anemia is defined by hemoglobin levels of 8 to 9.9 g/dL in women and 9 to 10.9 g/dL in men; severe anemia is defined by hemoglobin levels of 8 g/dL in women and 9 g/dL in men.
HMR mutations in MIPSS70+ v2.0 include ASXL1, SRSF2, EZH2, IDH1, IDH2, and U2AF1 Q157.
VHR karyotype defined as single/multiple abnormalities of −7, i(17q), inv(3)/ 3q21, 12p−/12p11.2, 11q−/11q23, or other autosomal trisomies not including +8/+9 (eg, +21, +19).